Petra Acquisition, Inc. Announces Share Redemption Backstop and Forward Purchase Agreements in Connection with Revelation Biosciences, Inc. Business Combination
December 22, 2021 09:00 ET
|
Revelation Biosciences, Inc.
NEW YORK and SAN DIEGO, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ: PAICU, PAIC, & PAICW) (“Perta”), a publicly traded special purpose acquisition company, announced today...
Petra Acquisition, Inc. Announces Special Meeting of Stockholders to Approve Business Combination with Revelation Biosciences, Inc.
December 16, 2021 16:15 ET
|
Revelation Biosciences, Inc.
-The Definitive Proxy Statement Has Been Filed with The Securities and Exchange Commission- -Stockholders Special Meeting Scheduled for January 6, 2022- NEW YORK and SAN DIEGO, Dec. 16, 2021 ...
Revelation Biosciences Inc. Appoints Joseph A. Bellanti, M.D. to Scientific Advisory Board
December 06, 2021 16:01 ET
|
Revelation Biosciences, Inc.
- Dr. Bellanti is Director of the International Center for Interdisciplinary Studies of Immunology and Professor of Pediatrics and Microbiology and Immunology at Georgetown University SAN DIEGO, Dec....
Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza
December 01, 2021 16:01 ET
|
Revelation Biosciences, Inc.
SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for...
Revelation Biosciences Inc. Announces Creation and Appointments to Scientific Advisory Board
November 29, 2021 09:00 ET
|
Revelation Biosciences, Inc.
- Dr. Catherine Blish is Professor of Medicine and Immunology and Associate Dean for Basic and Translational Research at the Stanford University School of Medicine – - Dr. Paul Spearman is...
Revelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhinitis and Chronic Nasal Congestion
November 15, 2021 09:00 ET
|
Revelation Biosciences, Inc.
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for...
Revelation Biosciences Inc. Engages Partnering Advisor, MedWorld Advisors, to Optimize Value of the Company’s Diagnostic Tool, REVID™
November 01, 2021 09:00 ET
|
Revelation Biosciences, Inc.
-REVID may have use by individuals in at-home settings for rapid monitoring of respiratory viral infections- -Offering broad detection of various viral infections, such as SARS-CoV-2, RSV, and...
Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)
October 25, 2021 16:01 ET
|
Revelation Biosciences, Inc.
-Anti-viral nasal drop REVTx-99 has potential to broadly prevent or treat respiratory infections including influenza, SARS-CoV-2, rhinovirus, RSV and pneumonia- -Intranasal immunomodulator,...
Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion
October 04, 2021 09:00 ET
|
Revelation Biosciences, Inc.
-Phase 1b study will investigate the efficacy of REVTx-99 on nasal symptoms elicited by nasal allergen challenge- -Top-line data anticipated in the first quarter of 2022- SAN DIEGO, Oct. 04, 2021 ...
Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections
September 28, 2021 09:00 ET
|
Revelation Biosciences, Inc.
- Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported flu symptoms- - Top-line data anticipated in the second quarter of 2022 - SAN DIEGO, Sept. 28, 2021 ...